文献速递淋巴瘤

我如何管理慢性淋巴细胞白血病患者的伊布替尼不耐受与并发症

How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia.
PubMed 文献 · Blood · 2019-01-14

伊布替尼自2014年获批后广泛用于慢性淋巴细胞白血病(CLL)的一线与挽救治疗,真实世界中房颤、出血、感染和关节痛等不良事件较临床试验更常见。本文介绍作者在真实世界CLL临床实践中处理伊布替尼常见不良事件的策略,并指出当前已有多种有效替代药物,可考虑换用其他CLL靶向治疗。

要点

  • 伊布替尼真实世界中房颤、出血、感染和关节痛等不良事件较早期临床试验更常见。
  • 不良事件管理需个体化,应结合患者及长期额外并发症风险制定策略。
  • 当前已有多种有效替代药物,可考虑换用其他CLL靶向治疗。

核心结论

  • 伊布替尼相关不良事件的管理常不能一概而论,必须根据患者及其长期额外并发症风险个体化处理。
  • 当前已有多种有效替代药物,可考虑换用其他CLL靶向治疗。
  • 鉴于伊布替尼在多个治疗领域持续扩展,需要研究该药不良事件的发病机制,并开展临床试验探讨治疗期间并发症的处理方法。

研究设计与样本

  • 本文为作者基于真实世界CLL临床实践的经验总结,介绍其处理伊布替尼常见不良事件的策略。

主要发现

  • 伊布替尼于2014年首次获批,现用于CLL患者的初始和挽救治疗。
  • 随着临床广泛使用,早期临床试验报告较少的常见和不常见不良事件在真实世界中更常遇到,尤其是房颤、出血、感染和关节痛。
  • 伊布替尼最初研发时CLL治疗选择有限,常导致带不良反应继续治疗。
  • 目前已有多种有效替代药物,可考虑换用其他CLL靶向治疗。

临床怎么用

  • 作者在真实世界CLL临床实践中采用个体化策略处理伊布替尼相关常见不良事件。
  • 作者认为当前已有多种有效替代药物,可考虑换用其他CLL靶向治疗。

局限性

  • 伊布替尼最初研发时CLL治疗选择有限,常导致带不良反应继续治疗。
  • 需要研究伊布替尼不良事件的发病机制,并开展临床试验探讨治疗期间并发症的处理方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic lymphocytic leukemia (CLL) therapy has changed dramatically with the introduction of several targeted therapeutics. Ibrutinib was the first approved for use in 2014 and now is used for initial and salvage therapy of CLL patients. With its widespread use in clinical practice, ibrutinib's common and uncommon adverse events reported less frequently in earlier clinical trials have been experienced more frequently in real-world practice. In particular, atrial fibrillation, bleeding, infections, and arthralgias have been reported. The management of ibrutinib's adverse events often cannot be generalized but must be individualized to the patient and their long-term risk of additional complications. When ibrutinib was initially developed, there were limited therapeutic alternatives for CLL, which often resulted in treating through the adverse events. At the present time, there are several effective alternative agents available, so transition to an alternative CLL directed therapy may be considered. Given the continued expansion of ibrutinib across many therapeutic areas, investigation of the pathogenesis of adverse events with this agent and also clinical trials examining therapeutic approaches for complications arising during therapy are needed. Herein, we provide strategies we use in real-world CLL clinical practice to address common adverse events associated with ibrutinib.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Stephens DM, Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood. 2019. PMID: 30642919. doi:10.1182/blood-2018-11-846808

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。